Literature DB >> 9665095

Energy expenditure, body composition, and glucose metabolism in lean and obese rhesus monkeys treated with ephedrine and caffeine.

J J Ramsey1, R J Colman, A G Swick, J W Kemnitz.   

Abstract

The administration of ephedrine and caffeine (E+C) has been proposed to promote weight loss by increasing energy expenditure and decreasing food intake. We tested this hypothesis in six lean (4-9% body fat) and six mildly to moderately obese (13-44% body fat) monkeys studied during a 7-wk control period, an 8-wk drug treatment period, and a 7-wk placebo period. During the drug treatment period, the monkeys were given ephedrine (6 mg) and caffeine (50 mg) orally three times per day. At the end of each period, a glucose tolerance test was performed, energy expenditure was measured, and body composition was determined. Treatment with E+C resulted in a decrease in body weight in the obese animals (P = 0.06). This loss in weight was primarily the result of a 19% reduction in body fat. Drug treatment also resulted in a decrease in body fat in the lean group (P = 0.05). Food intake was reduced by E+C only in the obese group (P < 0.05). Nighttime energy expenditure was increased by 21% (P < 0.03) in the obese group and 24% (P < 0.01) in the lean group with E+C treatment. Twenty-four-hour energy expenditure was higher in both groups during drug treatment. E+C did not produce systematic changes in glucoregulatory variables, whereas plasma leptin concentrations decreased in both groups with drug treatment. Overall, these results show that E+C treatment can promote weight loss through an increase in energy expenditure, or in some individuals, a combination of an increase in energy expenditure and a decrease in food intake.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9665095     DOI: 10.1093/ajcn/68.1.42

Source DB:  PubMed          Journal:  Am J Clin Nutr        ISSN: 0002-9165            Impact factor:   7.045


  5 in total

Review 1.  A review of standardized metabolic phenotyping of animal models.

Authors:  Jan Rozman; Martin Klingenspor; Martin Hrabě de Angelis
Journal:  Mamm Genome       Date:  2014-09-09       Impact factor: 2.957

Review 2.  Thermogenic drugs as a strategy for treatment of obesity.

Authors:  A Astrup
Journal:  Endocrine       Date:  2000-10       Impact factor: 3.925

3.  Muscle uncoupling protein 3 expression is unchanged by chronic ephedrine/caffeine treatment: results of a double blind, randomised clinical trial in morbidly obese females.

Authors:  Renata Bracale; Maria Letizia Petroni; Sergio Davinelli; Umberto Bracale; Giovanni Scapagnini; Michele O Carruba; Enzo Nisoli
Journal:  PLoS One       Date:  2014-06-06       Impact factor: 3.240

4.  Effects of Gambisan in overweight adults and adults with obesity: A retrospective chart review.

Authors:  Dae-Hyun Jo; Seunghoon Lee; Jae-Dong Lee
Journal:  Medicine (Baltimore)       Date:  2019-11       Impact factor: 1.889

5.  Chinese herbal medicine is associated with higher body weight reduction than liraglutide among the obese population: A real-world comparative cohort study.

Authors:  Yu-Ning Liao; Hsing-Yu Chen; Ching-Wei Yang; Pai-Wei Lee; Chiu-Yi Hsu; Yu-Tung Huang; Tsung-Hsien Yang
Journal:  Front Pharmacol       Date:  2022-09-09       Impact factor: 5.988

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.